Podcasts about diabetic macular edema

We discuss studies documenting the undertreatment of diabetic macular edema and possible strategies for alleviating it with Dr. Matthew Starr, Assistant Professor, Mayo Clinic, Rochester, Minnesota.

We review long term results from the PHOTON Study with Eric Schneider, MD, Tennessee Retina, Nashville, TM.

The experts discuss strategies, new-generation anti-vascular endothelial growth factors (VEGFs), and the evidence that supports their use. Credit available for this activity expires: 9/30/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1002951?ecd=bdc_podcast_libsyn_mscpedu

Dr. Drew Carey interviews medical student Jawad Muayad and Dr. Sami S. Dahr on the impact of systemic medications, including glucagon-like peptide-1 receptor agonists, fenofibrates, thiazolidinediones, and calcium channel blockers, on the risk of developing diabetic macular edema in patients with type 2 diabetes mellitus. From their Ophthalmology Retina article, “Influence of Common Medications on Diabetic Macular Edema in Type 2 Diabetes Mellitus” Influence of Common Medications on Diabetic Macular Edema in Type 2 Diabetes Mellitus. Muayad, Jawad et al. Ophthalmology Retina , Volume 9, Issue 6, 505 – 514 Sign up for the next Ophthalmology Journal Virtual Club on August 27, 2025, at https://store.aao.org/ophthalmology-virtual-journal-club.html Imagine enjoying an unforgettable night with colleagues from around the world and other Ophthalmology Journal Podcast listeners in Orlando. Illuminate is the must-attend social event of AAO 2025, and you're invited! Have drinks and heavy bites, listen to music and have fun on Oct. 18, while supporting ophthalmic education. Get your ticket when registering for AAO 2025 at aao.org/RegNow.

Interview with Arshad M. Khanani, MD, author of Continuous Ranibizumab via Port Delivery System vs Monthly Ranibizumab for Treatment of Diabetic Macular Edema: The Pagoda Randomized Clinical Trial. Hosted by Neil Bressler, MD. Related Content: Continuous Ranibizumab via Port Delivery System vs Monthly Ranibizumab for Treatment of Diabetic Macular Edema

Interview with Arshad M. Khanani, MD, author of Continuous Ranibizumab via Port Delivery System vs Monthly Ranibizumab for Treatment of Diabetic Macular Edema: The Pagoda Randomized Clinical Trial. Hosted by Neil Bressler, MD. Related Content: Continuous Ranibizumab via Port Delivery System vs Monthly Ranibizumab for Treatment of Diabetic Macular Edema

A JAMA study identified factors linked to loss to follow-up in diabetic retinopathy and macular edema patients, including male gender, distance from care, and sociodemographic disparities. In Vietnam, six months of levofloxacin therapy showed a non-significant reduction in multidrug-resistant tuberculosis, emphasizing the balance between benefits and tolerability. Finally, Phase II trial showed pancigromab's promise in addressing cancer cachexia, with weight gain and symptom improvement, supporting further research.

This podcast is published open access in Ophthalmology and Therapy and is fully citeable. You can access the original published podcast article through the Ophthalmology and Therapy website and by using this link: https://link.springer.com/article/10.1007/s40123-024-01053-3 All conflicts of interest can be found online. This podcast is intended for medical professionals. Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

Dr. Steve Edelman, an endocrinologist living with Type 1 diabetes, is joined by Dr. Nik London, an ophthalmologist specializing in retinal diseases such as Diabetic Retinopathy and Diabetic Macular Edema. Throughout this episode, they discuss eye complications and their effects on individuals with diabetes. They go into depth and breakdown Diabetic Retinopathy—a common eye complication found in individuals with diabetes. Diabetic retinopathy is a leading cause of blindness among individuals with diabetes, but through education, regular checkups, and advancements in treatment, the risk of vision loss can be significantly reduced. They explore how the condition can develop, its treatments, and the importance of regular eye checkups for individuals with diabetes. Dr. London shares his professional insights and knowledge on protecting eye health, advancements in retinal care, and how early detection can prevent vision loss among individuals with diabetes..Key Topics:What is diabetic retinopathy, and how does it develop?The different stages of diabetic retinopathy.What is Diabetic Macular Edema?How can DME be prevented?The importance of regular eye checkups for individuals with diabetes.How diabetes affects eye health and vision?Advances in the treatment of diabetic retinopathy Anti-VEGF injections.How do these injections work in regard to Diabetic Retinopathy?The different methods for preventing and treating diabetic retinopathy.How can early intervention save vision in patients with diabetes?Why early intervention is important when it comes to eye health.What to expect during a retinal exam and treatment process.Learn More:Video: Eye Complications – Prevention, Early Detection, and Aggressive TreatmentVideo: Routine Eye Exams: The What, When, How and WhyLearn more about DME and Vabysmo  ★ Support this podcast ★

Drs. David Eichenbaum and Priya Vakharia share their insights on biosimilars in the treatment of retinal disease in the United States.

We discuss the treatment results of high dose aflibercept in the eyes in the most severe quartile of diabetic macular edema with Dr. Roger Goldberg of Walnut Creek, California.

We discuss the importance of intensive therapy of DME, when using aflibercept for DME, as suggested by a review of real world cases from the Vestrum  data base, with Dr. Ferhina Ali, Assistant Professor of Ophthalmology, New York Medical College

We discuss the use of a topical agent for the treatment of diabetic macular edema with Dr. Arshad Khanani, Director of Research, Sierra Eye Associates, Associate Clinical Professor of Ophthalmology, University Nevada School of Medicine, Reno.

We discuss retinal drying in diabetic macular edema using the Iluvien implant with Dr. Michael Singer, Adjunct Professor, University of Texas Health Science Center, San Antonio.

We discuss the use of a novel treatment approach, senolytic therapy, for the treatment of diabetic macular edema with Dr. David Boyer, Adjunct Professor, USC Roski Eye Institute.

In our latest update, we discuss the relative drying effects of faricimab and aflibercept in the treatment of diabetic macular edema with Dr. Roger Goldberg.

We review the one year results of a clinical trial using high dose aflibercept (8mg) for the treatment of diabetic macular edema with Dr. David Boyer, Adjunct Clinical Professor of Ophthalmology, USC Roski Eye Institute

To characterize diabetic macular edema (DME) incidence in fellow eyes of patients treated for DME in the study eye.

We discuss the use of the port delivery system for the treatment of diabetic macular edema with Dr. Arshad Khanani, Director of Clinical Research, Sierra Eye Associates, Associate Clinical Professor, University of Nevada School of Medicine, Reno.

We discuss the use of corticosteroids, in particular, the dexamethasone implant in the management of diabetic macular edema with Dr. Kevin Blinder, Professor of Clinical Ophthalmology at Washington University School of Medicine, The Retina Institute.

Dr. Noemi Lois from Queens University in Belfast, UK discusses results of the DIAMONDS study, which was a prospective trial that looked into the effectiveness, safety, and cost-effectiveness of subthreshold micropulse laser (SML), compared with standard laser (SL), for diabetic macular edema (DME) with central retinal thickness (CRT) < 400 um. Referenced article: Lois N, Campbell C, Waugh N, Azuara-Blanco A, Maredza M, Mistry H, McAuley D, Acharya N, Aslam TM, Bailey C, Chong V, Downey L, Eleftheriadis H, Fatum S, George S, Ghanchi F, Groppe M, Hamilton R, Menon G, Saad A, Sivaprasad S, Shiew M, Steel DH, Talks JS, Doherty P, McDowell C, Clarke M; DIAMONDS Study Group. Diabetic Macular Edema and Diode Subthreshold Micropulse Laser: A Randomized Double-Masked Noninferiority Clinical Trial. Ophthalmology. 2023 Jan;130(1):14-27. doi: 10.1016/j.ophtha.2022.08.012. Epub 2022 Aug 13. PMID: 35973593.

Interview with David W. Hutton, PhD, author of Cost-effectiveness of Aflibercept Monotherapy vs Bevacizumab First Followed by Aflibercept If Needed for Diabetic Macular Edema. Hosted by Neil Bressler, MD.

Interview with David W. Hutton, PhD, author of Cost-effectiveness of Aflibercept Monotherapy vs Bevacizumab First Followed by Aflibercept If Needed for Diabetic Macular Edema. Hosted by Neil Bressler, MD.

Please visit answersincme.com/QND860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in ophthalmology discusses integrating anti–vascular endothelial growth factor (anti-VEGF) agents into treatment strategies for diabetic retinopathy (DR) and diabetic macular edema (DME). Upon completion of this activity, participants should be better able to: Review the clinical impact of approved VEGF-targeted agents for the treatment of DR and DME; Describe guideline-concordant, evidence-based strategies to select appropriate therapy for patients with DR with or without DME; and Outline patient-centered management approaches to enhance outcomes for patients with DR with or without DME receiving VEGF-targeted therapy.

Dr. Jhavery discusses results of DRCR Retina Protocol AC study which compared DME response to anti-VEGF injections in patients who received Aflibercept monotherapy vs those who started with Bevacizumab first and then switched to Aflibercept if needed.  Discussed article: Jhaveri CD, Glassman AR, Ferris FL 3rd, Liu D, Maguire MG, Allen JB, Baker CW, Browning D, Cunningham MA, Friedman SM, Jampol LM, Marcus DM, Martin DF, Preston CM, Stockdale CR, Sun JK; DRCR Retina Network. Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema. N Engl J Med. 2022 Aug 25;387(8):692-703. doi: 10.1056/NEJMoa2204225. Epub 2022 Jul 14. PMID: 35833805.

Please visit answersincme.com/YCQ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in ophthalmology discusses anti-VEGF treatment of diabetic retinopathy with or without diabetic macular edema. Upon completion of this activity, participants should be better able to: Review the clinical impact of approved VEGF-targeted agents for the treatment of DR and DME; Describe guideline-concordant, evidence-based strategies to select appropriate therapy for patients with DR with or without DME; and Outline patient-centered management approaches to enhance outcomes for patients with DR with or without DME receiving VEGF-targeted therapy.

We discuss a novel mechanism of action for the treatment of diabetic macular edema and neovascular AMD with Phase I/II trial results Dr. Raj Maturi, Midwest Eye Institute, Indiana University School of Medicine.

We discuss treat and extend versus alternate dosing strategies to treat center involving diabetic macular edema with Dr. Varun Chaudhary, Chief of Ophthalmology, Hamilton Regional Eye Center and Professor, McMaster University.

Drs. Shriji Patel, Safa Rahmani, and Sarwar Zahid join for a journal club discussion of three recent publications in major ophthalmology journals:Aflibercept or Bevacizumab First for Diabetic Macular Edema (https://www.nejm.org/doi/full/10.1056/NEJMoa2204225)Gas Tamponade for Postoperative Vitreous Hemorrhage Prevention (https://www.ajo.com/article/S0002-9394(22)00251-3/fulltext)Positioning after Macular Hole Surgery (https://ophthalmologyretina.org/article/S2468-6530(22)00322-0/fulltext)Relevant Financial Disclosures: Dr. Sridhar is a consultant for Alcon, DORC, Genentech, and Regeneron. Drs. Patel, Rahmani, and Zahid have no relevant disclosures.You can now claim CME credits via the AAO website. Visit https://www.aao.org/browse-multimedia?filter=Audi

Please visit answersincme.com/MYD860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in ophthalmology discusses best practices in diagnosis and treatment of diabetic retinopathy and diabetic macular edema. Upon completion of this activity, participants should be better able to: Recognize best practices to optimize the prompt and accurate diagnosis of diabetic retinopathy (DR) and diabetic macular edema (DME); and Describe guideline-concordant, evidence-based strategies to select appropriate therapy for patients with DR with or without DME.

The Journal RETINA is devoted exclusively to diseases of the retina and vitreous.  These podcasts are intended to bring to its listeners summaries of selected articles published in the current issue of this internationally acclaimed journal.

Dr. Drew Carey is joined by Dr. Tayyeba Ali and Google Software Engineer Pinal Bavishi to discuss their research collaboration with Google Health on a deep learning system that detects diabetic macular edema from their Ophthalmology Retina article, “Deep learning to detect optical coherence tomography-derived diabetic macular edema from retinal photographs: a multicenter validation study” Link to Google Health video discussed in the show: https://www.youtube.com/watch?v=2XQZQR477fg Deep Learning to Detect OCT-derived Diabetic Macular Edema from Color Retinal Photographs. Liu, Xinle et al. Ophthalmology Retina , Volume 6, Issue 5, 398 – 410.

We discuss the two year results of the first bispecific agent for the treatment of diabetic macular edema with Dr. John Wells III, from Palmetto Retina Clinic.

Drs. MacCumber and Singer explore the complex nature of caring for patients with diabetic macular edema including factors that impact arriving at the initial diagnosis, getting patients to the appropriate eye healthcare professional, and initiating appropriate therapy. They also describe the clinical factors that impact their treatment decision choices.

We discuss a phase I study examining the effect of plasma kvllikrein inhibition on diabetic macular edema with Dr. Arshad Khanani, Sierra Eye Associates, University of Nevada Reno.

Episode 339: Journal Club Including Discussion of Outcomes after Retinectomy for Proliferative Vitreoretinopathy, Gender Influence on Peer Review Process, and Diabetic Macular Edema and Retinopathy Rates Among Medicare Beneficiaries.Drs. Avni Finn, Katherine Talcott, and Priya Vakharia join for a journal club discussion of three recent publications in major ophthalmology journals.Retinectomy Visual Outcomes (https://www.ajo.com/article/S0002-9394(22)00096-4/fulltext)Authorship Gender and the Peer-Review Process (https://www.ajo.com/article/S0002-9394(22)00075-7/fulltext)Trends in Diabetic Retinopathy and Macular Edema (https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2789629)Relevant Financial Disclosures: None relevant.You can now claim CME credits via the AAO website. Visit https://www.aao.org/browse-multimedia?filter=Audi

Go online to PeerView.com/DRR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in ophthalmology discusses improving vision outcomes among Spanish-speaking patients with DR and DME, including those residing in rural areas. Upon completion of this CE activity, participants will be able to: Describe the barriers that Spanish-speaking individuals, especially those living in rural areas, frequently encounter when seeking a diagnosis and/or treatment of DR/DME, Construct coordinated care plans with multidisciplinary providers (eg, PCPs, endocrinologists, ophthalmologists, retina specialists) to provide timely diagnosis and treatment for Spanish-speaking patients with DR/DME, especially those residing in rural areas, Discuss the efficacy and safety of anti-VEGF agents in a manner that acknowledges and overcomes patient barriers regarding their use, Implement communication strategies (eg, telehealth, patient education tools, translation services) to help reduce barriers to care and enhance healthcare delivery toward the goal of improving DR/DME outcomes in Spanish-speaking patients, especially those residing in rural areas.

Go online to PeerView.com/DRR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in ophthalmology discusses improving vision outcomes among Spanish-speaking patients with DR and DME, including those residing in rural areas. Upon completion of this CE activity, participants will be able to: Describe the barriers that Spanish-speaking individuals, especially those living in rural areas, frequently encounter when seeking a diagnosis and/or treatment of DR/DME, Construct coordinated care plans with multidisciplinary providers (eg, PCPs, endocrinologists, ophthalmologists, retina specialists) to provide timely diagnosis and treatment for Spanish-speaking patients with DR/DME, especially those residing in rural areas, Discuss the efficacy and safety of anti-VEGF agents in a manner that acknowledges and overcomes patient barriers regarding their use, Implement communication strategies (eg, telehealth, patient education tools, translation services) to help reduce barriers to care and enhance healthcare delivery toward the goal of improving DR/DME outcomes in Spanish-speaking patients, especially those residing in rural areas.

Go online to PeerView.com/DRR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in ophthalmology discusses improving vision outcomes among Spanish-speaking patients with DR and DME, including those residing in rural areas. Upon completion of this CE activity, participants will be able to: Describe the barriers that Spanish-speaking individuals, especially those living in rural areas, frequently encounter when seeking a diagnosis and/or treatment of DR/DME, Construct coordinated care plans with multidisciplinary providers (eg, PCPs, endocrinologists, ophthalmologists, retina specialists) to provide timely diagnosis and treatment for Spanish-speaking patients with DR/DME, especially those residing in rural areas, Discuss the efficacy and safety of anti-VEGF agents in a manner that acknowledges and overcomes patient barriers regarding their use, Implement communication strategies (eg, telehealth, patient education tools, translation services) to help reduce barriers to care and enhance healthcare delivery toward the goal of improving DR/DME outcomes in Spanish-speaking patients, especially those residing in rural areas.

Go online to PeerView.com/DRR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in ophthalmology discusses improving vision outcomes among Spanish-speaking patients with DR and DME, including those residing in rural areas. Upon completion of this CE activity, participants will be able to: Describe the barriers that Spanish-speaking individuals, especially those living in rural areas, frequently encounter when seeking a diagnosis and/or treatment of DR/DME, Construct coordinated care plans with multidisciplinary providers (eg, PCPs, endocrinologists, ophthalmologists, retina specialists) to provide timely diagnosis and treatment for Spanish-speaking patients with DR/DME, especially those residing in rural areas, Discuss the efficacy and safety of anti-VEGF agents in a manner that acknowledges and overcomes patient barriers regarding their use, Implement communication strategies (eg, telehealth, patient education tools, translation services) to help reduce barriers to care and enhance healthcare delivery toward the goal of improving DR/DME outcomes in Spanish-speaking patients, especially those residing in rural areas.

Dr. Brian Roberts is a Senior VP and Head of Clinical Development at Rezolute which is developing first in class therapies in the treatment of metabolic diseases. In addition to working on a therapeutic for congenital hyperinsulinism, a rare disease, Rezolute is also in clinical trials with RZ402, an oral small molecule to treat diabetic macular edema which is showing an increase in prevalence due to the increase in the number of people suffering from diabetes. Brian explains, "DME or diabetic macular edema is a complication of diabetes. It's a subset of diabetic retinopathy. And like other complications of diabetes, the blood vessels in the eye become injured or corrupted. And this leads to inflammation in the leakage of fluid across the blood vessel into the eye. And in this case, into the macula of the retina, which is responsible for high-resolution vision. If that continues, it can result in progressive visual loss and even blindness." "Another problem with these therapies is that in some patients, they simply don't work. So the disease is not driven by vascular endothelial growth factor or VEGF. And so there really is a need for therapies that address a different mechanism and that allow the earlier treatment of disease before the disease gets difficult to control. And that's where our oral therapeutic with a different mechanism of action comes into play." "First and foremost, it represents a different mechanism, or a different way, to target the disease. RZ402 is a plasma kallikrein inhibitor. The kallikrein system is involved in the promotion of inflammation and vascular leakage. And it's part of normal physiology around the body to really promote the fight against infection or injury." @RezoluteBio #RezoluteBio #Biotech #DME #Medicines #Innovation #RareDisease #MetabolicDiseases #DiabeticMacularEdema #DiabeticRetinopathy RezoluteBio.com Download the transcript here

Dr. Brian Roberts is a Senior VP and Head of Clinical Development at Rezolute which is developing first in class therapies in the treatment of metabolic diseases. In addition to working on a therapeutic for congenital hyperinsulinism, a rare disease, Rezolute is also in clinical trials with RZ402, an oral small molecule to treat diabetic macular edema which is showing an increase in prevalence due to the increase in the number of people suffering from diabetes. Brian explains, "DME or diabetic macular edema is a complication of diabetes. It's a subset of diabetic retinopathy. And like other complications of diabetes, the blood vessels in the eye become injured or corrupted. And this leads to inflammation in the leakage of fluid across the blood vessel into the eye. And in this case, into the macula of the retina, which is responsible for high-resolution vision. If that continues, it can result in progressive visual loss and even blindness." "Another problem with these therapies is that in some patients, they simply don't work. So the disease is not driven by vascular endothelial growth factor or VEGF. And so there really is a need for therapies that address a different mechanism and that allow the earlier treatment of disease before the disease gets difficult to control. And that's where our oral therapeutic with a different mechanism of action comes into play." "First and foremost, it represents a different mechanism, or a different way, to target the disease. RZ402 is a plasma kallikrein inhibitor. The kallikrein system is involved in the promotion of inflammation and vascular leakage. And it's part of normal physiology around the body to really promote the fight against infection or injury." @RezoluteBio #RezoluteBio #Biotech #DME #Medicines #Innovation #RareDisease #MetabolicDiseases #DiabeticMacularEdema #DiabeticRetinopathy RezoluteBio.com Listen to the podcast here

Dr. David Dyer is the Chief Retina Specialist for Alimera Sciences, a publicly-traded company specializing in the development and commercialization of prescription ophthalmology treatments for the management of retinal diseases. Having high blood sugar over time can damage the retinal blood vessels that bring nutrients to the retina, creating diabetic retinopathy. Alimera has developed a delivery platform to inject their drug Iluvien into the eye to treat the resulting diabetic macular edema. David explains, "So with retinal diseases, you're usually talking about diseases within the nerve fiber layer of the retina, the retinal vessels, or in the tissue that is underneath the retina that supports some of the retinal function. And that includes diabetic retinopathy, macular degeneration, vein occlusions, sometimes you can get detachments of the retina, and there are many other disorders, but those are the most common." "The treatment for diabetic macular edema typically involves injecting medications into the eye. That sounds horrible, but we can actually numb up the eye, usually, with a series of numbing drops, and with a very tiny needle, we can inject medicine into the center of the eye, and that medicine diffuses into the retina." "Iluvien is a sustained-release steroid. It's a little pellet, like a little tiny piece of rice, and we can inject that into the eye in the office, and it slowly dissolves over a period of three years, and it releases a steroid into the eye. The steroid works specifically on diabetic macular edema or the swelling in the central vision, and it decreases swelling." @AlimeraSciences $ALIM #Iluvien #NewDayStudy #DMEandME #DiabeticMacularEdema #Ophthamology #Diabetes #Vision AlimeraSciences.com Download the transcript here

Dr. David Dyer is the Chief Retina Specialist for Alimera Sciences, a publicly-traded company specializing in the development and commercialization of prescription ophthalmology treatments for the management of retinal diseases. Having high blood sugar over time can damage the retinal blood vessels that bring nutrients to the retina, creating diabetic retinopathy. Alimera has developed a delivery platform to inject their drug Iluvien into the eye to treat the resulting diabetic macular edema. David explains, "So with retinal diseases, you're usually talking about diseases within the nerve fiber layer of the retina, the retinal vessels, or in the tissue that is underneath the retina that supports some of the retinal function. And that includes diabetic retinopathy, macular degeneration, vein occlusions, sometimes you can get detachments of the retina, and there are many other disorders, but those are the most common." "The treatment for diabetic macular edema typically involves injecting medications into the eye. That sounds horrible, but we can actually numb up the eye, usually, with a series of numbing drops, and with a very tiny needle, we can inject medicine into the center of the eye, and that medicine diffuses into the retina." "Iluvien is a sustained-release steroid. It's a little pellet, like a little tiny piece of rice, and we can inject that into the eye in the office, and it slowly dissolves over a period of three years, and it releases a steroid into the eye. The steroid works specifically on diabetic macular edema or the swelling in the central vision, and it decreases swelling." @AlimeraSciences $ALIM #Iluvien #NewDayStudy #DMEandME #DiabeticMacularEdema #Ophthamology #Diabetes #Vision AlimeraSciences.com Listen to the podcast here

The fluocinolone implant at 3 years is a useful modality for treating diabetic macular edema. Discussion with Dr. Michael Singer, Adjunct Professor University of Texas at San Antonio.

Diabetes is a major public health issue and every person diagnosed with diabetes is at risk of developing diabetic eye disease. Diabetic macular edema is a common complication of diabetic eye disease, which occurs when blood vessels in the retina are damaged and leak fluid into the macula causing blurry central vision. On this episode of ASRS's Retina Health for Life,  Dr. Diana Do of the Byers Eye Institute at the Stanford University School of Medicine joins Dr. Timothy Murray to discuss the importance of early diagnosis and immediate treatment of diabetic macular edema by a retina specialist which can prevent irreversible vision loss and blindness.  Resources: Access a downloadable fact sheet on Diabetic Macular Edema here: www.asrs.org/patients/retinal-diseases/20/macular-edema